A survey of senior figures in European biopharma companies has found that dealmaking and M&A are expected to increase, with ...

Klick Health's recent acquisition of Oxford PharmaGenesis reflects that shift. “Clearly for a lot of reasons that have been ...

Wegovy has since been joined in the UK market by Eli Lilly's oral GLP-1 agonist Foundayo (orforglipron), which was approved by the MHRA in August. Neither product is covered by the NHS, but can be ...

As antibody-drug conjugates (ADCs) continue to establish themselves as a cornerstone of modern oncology, breakthrough ...

Click Therapeutics has won the first-ever FDA approval for a treatment for the negative symptoms of schizophrenia – a digital ...

Day One Strategy’s second annual AI in Pharma State of Play report – Are Insights leaders seeing real commercial value from AI adoption yet? – addresses the challenges Pharma Insights teams are facing ...

When pharmaphorum last spoke with MRM Health founder and CEO Sam Possemiers at JP Morgan, he told us about his company’s microbiome-based therapy for ulcerative colitis. At LSX USA in Boston last ...

The governor of New York has said that rising cases of measles constitute a "statewide disaster emergency," the first such ...

AstraZeneca's pivot towards the US market has continued with the opening of a new R&D centre in the biotech hotspot of ...

This is not simply a broader role for Market Access. It is an emerging leadership capability for the healthcare business.

Industry is using AI to surface hidden patterns and accelerate decision-making in high-pressure launch environments. In a new ...

Shares in Vaxcyte have rocketed on the revelation of phase 3 trial data for its pneumococcal vaccine (PCV) candidate VAX-31, ...